Brown Rudnick represented Edwards Lifesciences Corp. (NYSE: EW) in connection with Edwards' participation as lead investor in a $50 million financing of CardioKinetix, Inc., a venture-backed medical device company pioneering a catheter-based treatment for heart failure. The deal included the grant to Edwards of an option to acquire CardioKinetix based on future regulatory milestones. The Brown Rudnick team representing Edwards was led by partners Rob Funsten and Katy Gardner and included associate Steve Cheng. Support for the transactions was provided by Brown Rudnick partner Vince Guglielmotti (tax).

To learn more about this deal, please read the following press releases:

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

CardioKinetix Completes $50 Million Financing and Signs Agreement With Edwards Lifesciences, Including Exclusive Option to Purchase